J.B. Chemicals & Pharmaceuticals Ltd.
JBCHEPHARM · NSE · Healthcare
₹2,217.8
-39.90 (-1.77%)
Our verdictOvervalued
Hold45/100
Quality71
Valuation25
Momentum77
Financial trend5
Intrinsic value
Our fair value
₹1,328.27
Overvalued by 40%
Price ₹2,217.8Range ₹701.85–₹1,954.69
With a 20% margin of safety, our buy-below price is ₹1,062.61.
A
Financial health 100/100
Altman Z 28.73 · Safe zone
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
Passed 8 of 13 checks62/100
- ✓ROE above 15%18.7%
- ✓Low debt (D/E < 0.5)0.00x
- ✓Positive free cash flow
- ✕Revenue growth > 10%-5%
- ✕Earnings growing-31%
- ✓Net margin ≥ 10%17.1%
- ✓Current ratio > 1.54.92
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 28.73
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-151W
+2.1%
1M
+4.1%
3M
+4.5%
6M
+23.9%
1Y
—
Our scores
Durability71
Valuation50
Momentum77
Analyst consensus target ₹2,258.22 (+2%) · 9 analysts
Key fundamentals
Market cap
₹35,609 Cr
P/E ratio
49.9
P/B ratio
8.56
EPS (TTM)
₹44.48
ROE
18.7%
Debt / Equity
0.00x
Profit margin
17.1%
Free cash flow
₹506 Cr
52-week high
₹2,257.7
-1.77% from high
52-week low
₹1,585.06
Dividend yield
0.8%
Beta
-0.02
SWOT snapshot
Strengths
- •Strong return on equity (18.7%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (17.1%).
- •Trading near its 52-week high.
- •Financially solid — Altman Z 28.73.
Threats
- •Earnings contracting year on year.
- •Trades ~40% above our estimated fair value.
About J.B. Chemicals & Pharmaceuticals Ltd.
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.